Background/Aims: Psoriasis plaque tests (PPTs) are important tools in the early phases of antipsoriatic drug development. Two distinct PPT design variants (open vs. occluded drug application) are commonly used, but no previous work has aimed to directly compare and contrast their performance. Methods: We compared the antipsoriatic efficacy of mapracorat 0.1% ointment and reference drugs reported in 2 separate studies, representing open and occluded PPT designs. The drug effect size was measured by sonography (mean change in echo-poor band thickness), chromametry, and standardized clinical assessment. Results: Antipsoriatic effects were detectable for the study drugs in both occluded and open PPTs. Differences between the potency of antipsoriatic drugs and vehicle were observable. The total antipsoriatic effect size appeared to be higher in the occluded PPT than the open PPT, despite the shorter treatment duration (2 vs. 4 weeks). Effect dynamics over time revealed greater differences between some study drugs in the open PPT compared to the occluded PPT. Conclusion: Taking the higher technical challenges for the open PPT into account, we recommend the occluded PPT as a standard screening setting in early drug development. In special cases, considering certain drug aspects or study objectives that would require procedural adaptations, an open PPT could be the better-suited design. Finally, both PPT models show clear advantages: classification as phase I studies, small number of psoriatic subjects, relatively short study duration, excellent discrimination between compounds and concentrations, parallel measurement of treatment response, and go/no go decisions very early in clinical development.

Keywords:
Psoriasis plaque test, Efficacy, Echo-poor band, Sonography, Clinical assessment
1.
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R: Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-485.
2.
Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, Chamilos G, Feldmeyer L, Marinari B, Chon S, Vence L, Riccieri V, Guillaume P, Navarini AA, Romero P, Costanzo A, Piccolella E, Gilliet M, Frasca L: The anti-microbial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 2014;5:5621.
3.
Arakawa A, Siewert K, Stöhr J, Besgen P, Kim SM, Rühl G, Nickel J, Vollmer S, Thomas P, Krebs S, Pinkert S, Spannagl M, Held K, Kammerbauer C, Besch R, Dornmair K, Prinz JC: Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 2015;212:2203-2212.
4.
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R: Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-174.
5.
Rafael A, Torres T: Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors. Eur J Dermatol 2016;26:3-8.
6.
Dumas KJ, Scholtz JR: The psoriasis bio-assay for topical corticosteroid activity. Acta Derm Venereol 1972;52:43-48.
7.
Wozel G, Mrowietz U: The psoriasis plaque test on the stage. Acta Derm 1999;99:43-48.
8.
Wozel G: Is the psoriasis plaque test still relevant in the age of biologicals? Hautarzt 2006;57:672-678.
9.
Weinstein GD, McCullough JL, Eaglestein WH, Golub A, Cornell RC, Stoughton RB, Clendenning W, Zackheim H, Maibach H, Kulp KR, King L, Baden HP, Tayler JS, Deneau DD: A clinical screening program for topical chemotherapeutic drugs in psoriasis. Arch Dermatol 1981;117:388-393.
10.
Katz M, Shaik Z, Maibach HI: Scholtz-Dumas psoriasis small plaque bioassay. J Dermatol Treat 2000;11:15-19.
11.
Shargel L, Kanfer I: Generic Drug Product Development: Specialty Dosage Forms. New York, 2010, pp 88-90.
12.
Bangha E, Elsner P: Evaluation of topical anti-psoriatic treatment by chromametry, visiometry and 20-MHz ultrasound in the psoriasis plaque test. Skin Pharmacol 1996;9:298-306.
13.
Savolainen L, Kontinen J, Alatalo E, Röning J, Oikarinen A: Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine version methods in following the treatment of psoriasis. Acta Derm Venereol 1998;78:466-467.
14.
Hoffmann K, el Gammal S, Schwarze H, Dschirka T, Altmeyer P: Examination of psoriasis vulgaris using 20-MHz B-scan ultrasound; in Altmeyer P, el Gammal S, Hoffmann K (eds): Ultrasound in Dermatology. Heidelberg, Springer, 1992, pp 244-249.
15.
el Gammal S, Hoffmann K, Auer T, Korten M, Altmeyer P, Höss A, Ermert H: A 50-MHz high resolution ultrasound imaging system for dermatology; in Altmeyer P, el Gammal S, Hoffmann K (eds): Ultrasound in Dermatology. Heidelberg, Springer, 1992, pp 297-322.
16.
el Gammal S, Auer T, Popp C, Hoffmann K, Altmeyer P, Passmann C, Ermert H: Psoriasis vulgaris in 50-MHz B-scan ultrasound: characteristic features of stratum corneum, epidermis and dermis. Acta Derm Venereol Suppl (Stockh) 1994;74:173-176.
17.
Hoffmann K, Dschirka T, Schwarze H, el-Gammal S, Matthes U, Hoffmann A, Altmeyer P: 20-MHz sonography, colorimetry and image analysis in the evaluation of psoriasis vulgaris. J Dermatol Sci 1995;9:103-110.
18.
Gupta AK, Turnbull DH, Harasiewicz KA, Shum DT, Watteel GN, Foster S, Sauder DN: The use of high-frequency ultrasound as a method of assessing the severity of a plaque of psoriasis. Arch Dermatol 1996;132:658-662.
19.
Snape SD, Wigger-Alberti W, Goehring UM: A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a psoriasis plaque test. Br J Dermatol 2016;175:479-486.
20.
Geilen CC, Mrowietz U: Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris. J Am Acad Dermatol 2000;42:837-840.
21.
Buder K, Knuschke P, Wozel G: Evaluation of methylprednisolone aceponate, tacrolimus and combination thereof in the psoriasis plaque test using sum score, 20-MHz-ultrasonography and optical coherence tomography. Int J Clin Pharmacol Ther 2010;48:814-820.
22.
Lee CS, Koo J: The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison. J Drugs Dermatol 2009;8:751-755.
23.
Queille-Roussel C, Hoffmann V, Ganslandt C, Hansen KK: Comparison of the anti-psoriatic effect and tolerability of calcipotriol-containing products in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. Clin Drug Investig 2012;32:613-619.
24.
Queille-Roussel C, Hoffmann V, Enevold A, Ganslandt C: Use of a psoriasis plaque test in the development of a gel formulation of calcipotriol and betamethasone dipropionate for scalp psoriasis. J Dermatolog Treat 2013;24:250-254.
25.
Barry BW, Woodford R: Comparative bioavailability of proprietary topical corticoid preparations; vasoconstrictor assays on thirty creams and gels. Br J Dermatol 1974;91:323-338.
26.
Broby-Johansen U, Karlsmark T, Petersen LJ, Serup J: Ranking of the anti-psoriatic effect of various topical corticosteroids applied under a hydrocolloid dressing - skin-thickness, blood-flow and colour measurements compared to clinical assessments. Clin Exp Dermatol 1990;15:343-348.
27.
Lévy J, Gassmueller J, Schroeder G, Audring H, Soennichschen N: Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness. Skin Pharmacol 1994;7:231-236.
28.
Cucoş M, Crişan M, Lenghel M, Dudea M, Croitoru R, Dudea SM: Conventional ultrasonography and sonoelastography in the assessment of plaque psoriasis under topical corticosteroid treatment - work in progress. Med Ultrason 2014;16:107-113.
29.
Queille-Roussel C, Clonier F, Olesen M: Alternative treatment with calcipotriol plus betamethasone dipropionate gel in psoriasis vulgaris using a short-contact approach. Br J Dermatol 2014;171:1596-1598.
30.
Queille-Roussel C, Olesen M, Villumsen J, Lacour JP: Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin Drug Investig 2015;35:239-245.
31.
Christophers E, Mrowietz U: The inflammatory infiltrate in psoriasis. Clin Dermatol 1995;13:131-135.
32.
Jacobi A, Mayer A, Augustin M: Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review. Dermatol Ther 2015;5:1-18.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.